非甾体抗炎药(NSAIDs)对结直肠肿瘤的预防价值
The Value of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Prevention of Colorectal Cancer
DOI: 10.12677/acm.2025.1561757, PDF,   
作者: 韩鸿俊, 李彦冬*：北华大学附属医院普外二科，吉林 吉林
关键词: 非甾体抗炎药；结直肠肿瘤；预防；NSAIDs； Colorectal Cancer； Prevention
摘要: 非甾体抗炎药(Nonsteroidal Anti-Inflammatory Drugs, NSAIDs)是一类不含有甾体结构的抗炎药，代表药物阿司匹林，临床上主要用于心脑缺血性疾病的一级预防与治疗。随着近年来研究的深入，阿司匹林能够降低结直肠肿瘤的风险甚至显著降低病人的死亡率。美国预防服务工作组(USPSTF)发布一项建议，将低剂量阿司匹林列为成人结直肠癌等多种肿瘤的二级预防措施。阿司匹林的这种作用可能通过抑制环氧化酶、抑制NF-κB及抑制CDH1甲基化等机制实现。本文旨在对NSAIDs预防结直肠癌及其作用机制的研究进行综述。
Abstract: Non-steroidal anti-inflammatory Drugs (Nonsteroidal Anti-Inflammatory Drugs, NSAIDs) are a class does not contain the structure of the steroidal anti-inflammatory drug, on behalf of the drug aspirin, clinically is mainly used for the primary prevention and treatment of ischemic cerebrovascular disease. With the deepening of the research in recent years, aspirin can reduce the risk of colorectal cancer or even significantly reduce mortality in patients. The U.S. Preventive Services Task Force (USPSTF) issued a recommendation for listing low-dose aspirin as a secondary prevention measure for a variety of tumors, including colorectal cancer, in adults. This effect of aspirin may be achieved through the inhibition of cyclooxygenase, NF-κB and CDH1 methylation. The purpose of this paper is to study of NSAIDs to prevent colorectal cancer and its mechanism of action were reviewed.
文章引用：韩鸿俊, 李彦冬. 非甾体抗炎药(NSAIDs)对结直肠肿瘤的预防价值[J]. 临床医学进展, 2025, 15(6): 530-536. https://doi.org/10.12677/acm.2025.1561757

参考文献

[1] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[2] 徐璟, 孙国平. 低剂量阿司匹林预防结直肠癌的研究进展[J]. 安徽医药, 2019, 23(9): 1697-1700.
[3] Rothwell, P.M., Wilson, M., Elwin, C., Norrving, B., Algra, A., Warlow, C.P., et al. (2010) Long-Term Effect of Aspirin on Colorectal Cancer Incidence and Mortality: 20-Year Follow-Up of Five Randomised Trials. The Lancet, 376, 1741-1750. [Google Scholar] [CrossRef] [PubMed]
[4] Lee, K., Chung, K., Chen, H., Cheng, K., Wu, K. and Song, L. (2023) Potential Beneficial Effects of Long-Term Aspirin Use on the Prevalence of Colorectal Cancer: A Population-Based Study of the US Nationwide Inpatient Sample. Cancer Causes & Control, 35, 477-486. [Google Scholar] [CrossRef] [PubMed]
[5] Giampieri, R., Restivo, A., Pusceddu, V., Del Prete, M., Maccaroni, E., Bittoni, A., et al. (2017) The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients with Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer, 16, 38-43. [Google Scholar] [CrossRef] [PubMed]
[6] 高雪芹, 孙素玲, 孙方利, 等. 非甾体类抗炎药对肠息肉及结、直肠癌保护作用的病例对照研究[J]. 中华预防医学杂志, 2002(5): 45-48.
[7] Baron, J.A., Cole, B.F., Sandler, R.S., Haile, R.W., Ahnen, D., Bresalier, R., et al. (2003) A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. New England Journal of Medicine, 348, 891-899. [Google Scholar] [CrossRef] [PubMed]
[8] Nafisi, S., Randel, K.R., Støer, N.C., Veierød, M.B., Hoff, G., Holme, Ø., et al. (2023) Association between Use of Low-Dose Aspirin and Detection of Colorectal Polyps and Cancer in a Screening Setting. Digestive and Liver Disease, 55, 1126-1132. [Google Scholar] [CrossRef] [PubMed]
[9] Iwama, T., Tamura, K., Morita, T., Hirai, T., Hasegawa, H., Koizumi, K., et al. (2004) A Clinical Overview of Familial Adenomatous Polyposis Derived from the Database of the Polyposis Registry of Japan. International Journal of Clinical Oncology, 9, 308-316. [Google Scholar] [CrossRef] [PubMed]
[10] Ishikawa, H., Wakabayashi, K., Suzuki, S., Mutoh, M., Hirata, K., Nakamura, T., et al. (2012) Preventive Effects of Low‐dose Aspirin on Colorectal Adenoma Growth in Patients with Familial Adenomatous Polyposis: Double‐Blind, Randomized Clinical Trial. Cancer Medicine, 2, 50-56. [Google Scholar] [CrossRef] [PubMed]
[11] Burn, J., Bishop, D.T., Chapman, P.D., Elliott, F., Bertario, L., Dunlop, M.G., et al. (2011) A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis. Cancer Prevention Research, 4, 655-665. [Google Scholar] [CrossRef] [PubMed]
[12] Sandler, R.S., Halabi, S., Baron, J.A., Budinger, S., Paskett, E., Keresztes, R., et al. (2003) A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer. New England Journal of Medicine, 348, 883-890. [Google Scholar] [CrossRef] [PubMed]
[13] Logan, R.F.A., Grainge, M.J., Shepherd, V.C., Armitage, N.C. and Muir, K.R. (2008) Aspirin and Folic Acid for the Prevention of Recurrent Colorectal Adenomas. Gastroenterology, 134, 29-38. [Google Scholar] [CrossRef] [PubMed]
[14] 刘军, 赵妙, 何均辉, 等. 口服阿司匹林预防结直肠腺瘤行内镜切除术后复发的临床研究[J]. 消化肿瘤杂志(电子版), 2016, 8(2): 81-85.
[15] Pommergaard, H., Burcharth, J., Rosenberg, J. and Raskov, H. (2016) Advanced Age Is a Risk Factor for Proximal Adenoma Recurrence Following Colonoscopy and Polypectomy. Journal of British Surgery, 103, e100-e105. [Google Scholar] [CrossRef] [PubMed]
[16] Patrignani, P., Sacco, A., Sostres, C., Bruno, A., Dovizio, M., Piazuelo, E., et al. (2017) Low‐Dose Aspirin Acetylates Cyclooxygenase‐1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. Clinical Pharmacology & Therapeutics, 102, 52-61. [Google Scholar] [CrossRef] [PubMed]
[17] Domingo, E., Church, D.N., Sieber, O., Ramamoorthy, R., Yanagisawa, Y., Johnstone, E., et al. (2013) Evaluation of pik3ca Mutation as a Predictor of Benefit from Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. Journal of Clinical Oncology, 31, 4297-4305. [Google Scholar] [CrossRef] [PubMed]
[18] Fedirko, V., McKeown‐Eyssen, G., Serhan, C.N., Barry, E.L., Sandler, R.S., Figueiredo, J.C., et al. (2017) Plasma Lipoxin A4 and Resolvin D1 Are Not Associated with Reduced Adenoma Risk in a Randomized Trial of Aspirin to Prevent Colon Adenomas. Molecular Carcinogenesis, 56, 1977-1983. [Google Scholar] [CrossRef] [PubMed]
[19] Chan, A.T. (2009) Aspirin Use and Survival after Diagnosis of Colorectal Cancer. JAMA, 302, 649-658. [Google Scholar] [CrossRef] [PubMed]
[20] Chan, A.T., Ogino, S. and Fuchs, C.S. (2007) Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. New England Journal of Medicine, 356, 2131-2142. [Google Scholar] [CrossRef] [PubMed]
[21] Petrera, M., Paleari, L., Clavarezza, M., Puntoni, M., Caviglia, S., Briata, I.M., et al. (2018) The ASAMET Trial: A Randomized, Phase II, Double-Blind, Placebo-Controlled, Multicenter, 2 × 2 Factorial Biomarker Study of Tertiary Prevention with Low-Dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. BMC Cancer, 18, Article No. 1210. [Google Scholar] [CrossRef] [PubMed]
[22] Yu, H., Yu, L., Yang, Y., Luo, H., Yu, J., Meier, J.J., et al. (2003) Increased Expression of RelA/Nuclear Factor-κB Protein Correlates with Colorectal Tumorigenesis. Oncology, 65, 37-45. [Google Scholar] [CrossRef] [PubMed]
[23] Drew, D.A., Chin, S.M., Gilpin, K.K., Parziale, M., Pond, E., Schuck, M.M., et al. (2017) Aspirin Intervention for the Reduction of Colorectal Cancer Risk (ASPIRED): A Study Protocol for a Randomized Controlled Trial. Trials, 18, Article No. 50. [Google Scholar] [CrossRef] [PubMed]
[24] Cha, Y.I. and DuBois, R.N. (2007) NSAIDs and Cancer Prevention: Targets Downstream of COX-2. Annual Review of Medicine, 58, 239-252. [Google Scholar] [CrossRef] [PubMed]
[25] Chulada, P.C., Loftin, C.D., Winn, V.D., Young, D.A., Tiano, H.F., Eling, T.E., et al. (1996) Relative Activities of Retrovirally Expressed Murine Prostaglandin Synthase-1 and-2 Depend on Source of Arachidonic Acid. Archives of Biochemistry and Biophysics, 330, 301-313. [Google Scholar] [CrossRef] [PubMed]
[26] Drew, D.A. and Chan, A.T. (2021) Aspirin in the Prevention of Colorectal Neoplasia. Annual Review of Medicine, 72, 415-430. [Google Scholar] [CrossRef] [PubMed]
[27] Wargovich, M.J., Jimenez, A., McKee, K., Steele, V.E., Velasco, M., Woods, J., et al. (2000) Efficacy of Potential Chemopreventive Agents on Rat Colon Aberrant Crypt Formation and Progression. Carcinogenesis, 21, 1149-1155. [Google Scholar] [CrossRef] [PubMed]
[28] VANE, J.R. (1971) Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nature New Biology, 231, 232-235. [Google Scholar] [CrossRef] [PubMed]
[29] Vane, J.R. (1983) Adventures and Excursions in Bioassay—The Stepping Stones to Prostacyclin. Postgraduate Medical Journal, 59, 743-758. [Google Scholar] [CrossRef] [PubMed]
[30] Chattopadhyay, M., Goswami, S., Rodes, D.B., Kodela, R., Velazquez, C.A., Boring, D., et al. (2010) No-Releasing NSAIDs Suppress NF-κB Signaling in Vitro and in Vivo through S-Nitrosylation. Cancer Letters, 298, 204-211. [Google Scholar] [CrossRef] [PubMed]
[31] Guo, J., Zhu, Y., Yu, L., Li, Y., Guo, J., Cai, J., et al. (2021) Aspirin Inhibits Tumor Progression and Enhances Cisplatin Sensitivity in Epithelial Ovarian Cancer. PeerJ, 9, e11591. [Google Scholar] [CrossRef] [PubMed]
[32] Guo, H., Liu, J., Ben, Q., Qu, Y., Li, M., Wang, Y., et al. (2016) The Aspirin-Induced Long Non-Coding RNA OLA1P2 Blocks Phosphorylated STAT3 Homodimer Formation. Genome Biology, 17, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
[33] Wu, Y., Wang, X., Xu, F., Zhang, L., Wang, T., Fu, X., et al. (2020) The Regulation of Acetylation and Stability of HMGA2 via the HBXIP-Activated Akt-PCAF Pathway in Promotion of Esophageal Squamous Cell Carcinoma Growth. Nucleic Acids Research, 48, 4858-4876. [Google Scholar] [CrossRef] [PubMed]
[34] Drew, D.A. and Chan, A.T. (2021) Aspirin in the Prevention of Colorectal Neoplasia. Annual Review of Medicine, 72, 415-430. [Google Scholar] [CrossRef] [PubMed]

为你推荐